2023-09-12 04:03:15
2023-09-12 09:29 Compiled by United Daily News Lu Silun/Real-time reporting
Archyde.com reported that the U.S. Food and Drug Administration (FDA) approved the new Pfizer/BNT and Moderna vaccines on the 11th, focusing on the latest popular new coronavirus variant XBB.1.5, and vaccinations will be available as soon as this week; while the Novavax vaccine booster dose is pending for the disease. The Center for Control and Prevention (CDC) will convene an advisory group to confirm the vaccination targets before releasing them.
The new vaccines from Pfizer and Moderna target the XBB.1.5 strain and are intended for use in children over 12 years old, with emergency authorization applicable to children aged 6 months to 11 years old.
Peter Marks, director of the Center for Biologics and Evaluation (CBER) under the U.S. Food and Drug Administration, called on the public to take the vaccine with confidence. “The safety, effectiveness and production quality of the new vaccine meet the strict review standards of the Food and Drug Administration. It is recommended that all qualified Targets are actively vaccinated.”
At the end of summer this year, the new variant EG.5, nicknamed “Eris”, spread rapidly in the United States and other countries. At the same time, public health experts were worried regarding the highly mutated variant BA.2.86 detected in many countries.
The U.S. Food and Drug Administration approved the new Pfizer/BNT and Moderna vaccines on the 11th, focusing on the latest popular new coronavirus variant…
Novavax shares closed down regarding 13% at $7.82.
United States Moderna FDA Pfizer vaccine
Further reading
1694507240
#epidemic #rise #late #summerUS #FDA #approves #Pfizer #Moderna #XBB.1.5 #vaccines #vaccination #week #News #Global
